Jaguar Health, Inc. (NASDAQ:JAGX)
About the company
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.
Gross Margin (in %)
Operating Margin (in %)
Net Margin (in %)
Dividend Yield (in %)
|Name||Ticker||Market capitalization (in USD Million)||Revenues (in USD Million)||Price/Book||Price/Earning||Net margin (in %)|
|BridgeBio Pharma, Inc.||BBIO||3821.18||41.00||10.06||-13.16||-718.08|
|Taro Pharmaceutical Industries Ltd.||TARO||2474.94||645.00||1.18||10.26||37.88|
|Abeona Therapeutics, Inc.||ABEO||186.62||3.00||1.91||-1.84||75.95|
|Kindred Biosciences, Inc.||KIN||151.71||4.00||2.53||-2.22||None|
|Cocrystal Pharma, Inc.||COCP||62.65||2.00||2.29||-1.08||-733.84|
|China Pharma Holdings, Inc.||CPHI||23.76||10.00||2.84||-1.10||-214.63|
|Jaguar Health, Inc.||JAGX||6.21||5.00||4.60||0.09||-887.14|
Latest insider transactions
|Date||Role||Name||Transaction||Quantity||Quantity Owned After|
Jaguar Health Submits Final Major Regulatory Filing for Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in Dogs
Working dogs, including search and rescue, military and sled dogs, often suffer diarrhea as a result of engaging in long periods of intense, off-leash exercise. "Elite athletes of all species tend to ...
OASIS CAPITAL LLC REPORTS 9.99% PASSIVE STAKE IN JAGUAR HEALTH AS OF JULY 7- SEC FILING Source text (bit.ly/3iEuBAL) Further company coverage: Our Standards:The Thomson Reuters Trust Principles.
(NASDAQ:JAGX) subsidiary, Napo Pharmaceuticals has completed the filing of the IND application with the FDA for crofelemer (Mytesi) for the planned indication of prophylaxis and symptomatic relief of ...
Jaguar Health seeks US FDA’s Center for Veterinary Medicine approval for Canalevia to treat exercise-induced diarrhea in dogs
Jaguar Health announced that it has submitted to the US Food and ... Jaguar's wholly owned subsidiary, Napo Pharmaceuticals, Inc. (Napo), currently markets another form of crofelemer, Mytesi, the only ...
SAN FRANCISCO, CA / ACCESSWIRE / June 19, 2020 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company") announced today that the Board of Directors of the Company (the "Board") adopted the Jaguar ...
Pilar Mine Achieves New Record Production Strong Free Cash Flow and Liquidity Operational Update on COVID-19 Action Plan TORONTO, ON / / July 7, 2020 / Jaguar ...
The man accused of driving a Jaguar on to a closed Seattle freeway and hitting two protesters, killing one, is scheduled to appear in court Monday.